The co-IP experiment data we present here indicates that in FTD there may also be some basal tau:CRBN association, and thus, rather than targeting a ‘neo-substrate’, QC-01–175 may be promoting efficacy of a physiological process, increasing the probability of successful tau degradation in vivo. Here, MAPT is linked to frontotemporal dementia.